In your state, you are required to confirm you wish to access this information. Please enter 'QLD' or 'WA' in the field below to continue.

No thanks

Breast implant suspended from Australian market

Female looking at a sunset

The Therapeutic Goods Association (TGA) has imposed a 6 month suspension on Cereform silicone gel-filled breast implants and associated sizers from the Australian Register of Therapeutic Goods.

Since 2009, about 4800 of the implants were sold in Australia. The action taken by the TGA will now prevent the devices from being supplied to the Australian market.

Earlier this year the French government recalled the Cereform silicone gel-filled breast implants and associated sizers as a result of the manufacturer’s failure to comply with international sterilisation standards.  However, French authorities have stated that the issue is one regarding regulatory non-compliance and have emphasised that no specific risks have been associated with the devices.

Initially the TGA contacted surgeons and ensured that any planned procedures involving implanting the devices were cancelled.  However, in March this year the Australian distributor, Medical Vision Australia Plastic & Cosmetic, took further action and launched its own recall of the implants and associated sizers.

Although the TGA has now supported this recall by suspending the devices from the Australian Register of Therapeutic Goods, the TGA maintains that it is not aware of any specific risks to Australian consumers.  The TGA has clarified that while there has been an identified issue of regulatory non-compliance with international sterilisation standards, this does not mean that the implants or associated sizers were unsterile at the time of manufacture or supply.

The recall and suspension of the Cereform breast implants and associated sizers has given rise to renewed calls for the establishment of an Australian national breast device registry.  Supporters emphasise the need for a registry in order ensure any issues with breast devices are detected as soon as possible.  Although the Federal government had committed $3.6 million to the initiative, the registry has not yet advanced beyond a pilot project, and further action is required to enable its development.

Written by Shine Lawyers on . Last modified: September 21, 2017.

Join the discussion

Share this article:

There are 0 comments. Be the first!

Faulty High-tech braking systems: Subaru and Honda Recalls

The safety of cars with automatic braking systems have been called into question with car manufactures issuing worldwide recalls in response to faulty program software. Car manufactures Subaru and Honda have announced large recalls due to malfunctioning technology designed to prevent rear-end crashes and avoid hitting pedestrians, yet instead are putting the vehicles at risk […]

Read more

China-Australia Free Trade Agreement: potential commercial implications

The China-Australia Free Trade Agreement (ChAFTA) was signed on the 17th June 2015, implementing a foundation in the next phase of inter-economic relationships between Australia and China. The potential for the ChAFTA to create opportunities for Australia is evident, with China accounting for Australia’s largest export market for goods and services and a nearly a […]

Read more

Blood thinner Xarelto linked to potentially fatal bleeding

Clinical trials and post-market experience have linked widely used blood-thinning drug Xarelto and similar anticoagulants to incidences of major bleeding, some of which have been fatal. Xarelto works to reduce the tendency of blood to form clots and may be prescribed to prevent or treat blood clots in the brain, lungs, legs, or veins. Patients […]

Read more

Blood thinner to face action over fatal bleeding

A new blood thinning agent, marketed for having minimal side effects, may face litigation in the U.S. involving claims the medication has been linked to potentially fatal bleeding complications. Eliquis (Apixaban) is an anti-clotting agent used for persons with a heart irregularity known as atrial fibrillation to reduce risk of stroke. It is also used […]

Read more

Call Us Now

Our friendly consultants are available to talk Monday to Friday, 8:15am to 6:00pm AEST.

1800 618 851

Live Chat

Chat with Shine Lawyers through the livechat system without leaving your computer. No downloading, completely private and best of all - its easy to use.

Start a live chat now

Enquire Now

Enquire now